Berling R, Borgström A, Ohlsson K
Department of Anesthesiology, Lund University, Malmö University Hospital, Sweden.
Int J Pancreatol. 1998 Aug;24(1):9-17. doi: 10.1007/BF02787525.
Although high-dose aprotinin given intraperitoneally to patients with severe acute pancreatitis seems to inhibit activated trypsin in the peritoneal cavity, the treatment has little effect on the balance between proteases and antiproteases. Plasma levels of leukocyte proteases were high in all the patients, indicating leukocyte activation to be an important feature of the pathophysiology of severe acute pancreatitis. A surprise finding was that the patients had higher peritoneal levels of pancreatic secretory trypsin inhibitor (PSTI) after the lavage procedure.
Although most studies have shown protease inhibitor therapy to have little or no effect on acute pancreatitis, in an earlier study we found that very high doses of the protease inhibitor aprotinin given intraperitoneally to patients with severe acute pancreatitis seemed to reduce the need of surgical treatment for pancreatic necrosis. In the present study we have further analyzed plasma and peritoneal samples from the same patients to ascertain whether the aprotinin treatment affects the balance between proteases and endogenous antiproteases.
In a prospective double-blind randomized multicenter trial, 48 patients with severe acute pancreatitis were treated with intraperitoneal lavage. One group (aprotinin group, n = 22) was also treated with high doses (20 million KIU given over 30 h) of aprotinin intraperitoneally. The remaining 26 patients made up the control group. The protease-antiprotease balance was studied by measuring immunoreactive anionic trypsin (irAT), cationic trypsin (irCT), complexes between cationic trypsin and alpha 1-protease inhibitor (irCT-alpha 1 PI), leukocyte elastase and neutrophil proteinase 4 (NP4), as well as the endogenous protease inhibitors, pancreatic secretory trypsin inhibitor (PSTI), alpha 2-macroglobulin (alpha 2M), alpha 1-protease inhibitor (alpha 1 PI), antichymotrypsin (ACHY), and secretory leukocyte protease inhibitor (SLPI). Intraperitoneal levels were studied before and after the lavage procedure, and plasma levels were followed for 21 d.
The control group had lower plasma levels of SLPI and analysis of peritoneal fluid showed the reduction of irCT-alpha 1 PI to be more pronounced in the aprotinin group. None of the other variables measured differed significantly between the two groups. All patients had very high levels of leukocyte elastase and NP4 both in peritoneal exudate and in plasma. Peritoneal levels of PSTI were higher after the lavage procedure in contrast to the other measured variables that all showed lower peritoneal levels after the lavage.
尽管对重症急性胰腺炎患者腹腔内给予高剂量抑肽酶似乎能抑制腹腔内活化的胰蛋白酶,但该治疗对蛋白酶和抗蛋白酶之间的平衡影响甚微。所有患者血浆中的白细胞蛋白酶水平都很高,这表明白细胞活化是重症急性胰腺炎病理生理学的一个重要特征。一个意外的发现是,灌洗术后患者腹腔内的胰分泌性胰蛋白酶抑制剂(PSTI)水平较高。
尽管大多数研究表明蛋白酶抑制剂疗法对急性胰腺炎几乎没有效果或根本没有效果,但在一项早期研究中,我们发现对重症急性胰腺炎患者腹腔内给予非常高剂量的蛋白酶抑制剂抑肽酶似乎能减少胰腺坏死的手术治疗需求。在本研究中,我们进一步分析了同一批患者的血浆和腹腔样本,以确定抑肽酶治疗是否会影响蛋白酶和内源性抗蛋白酶之间的平衡。
在一项前瞻性双盲随机多中心试验中,48例重症急性胰腺炎患者接受了腹腔灌洗治疗。一组(抑肽酶组,n = 22)还接受了腹腔内高剂量(30小时内给予2000万KIU)的抑肽酶治疗。其余26例患者组成对照组。通过测量免疫反应性阴离子胰蛋白酶(irAT)、阳离子胰蛋白酶(irCT)、阳离子胰蛋白酶与α1 - 蛋白酶抑制剂之间的复合物(irCT - α1 PI)、白细胞弹性蛋白酶和中性粒细胞蛋白酶4(NP4),以及内源性蛋白酶抑制剂胰分泌性胰蛋白酶抑制剂(PSTI)、α2 - 巨球蛋白(α2M)、α1 - 蛋白酶抑制剂(α1 PI)、抗胰凝乳蛋白酶(ACHY)和分泌型白细胞蛋白酶抑制剂(SLPI)来研究蛋白酶 - 抗蛋白酶平衡。在灌洗术前和术后研究腹腔内水平,并对血浆水平进行21天的跟踪监测。
对照组的血浆SLPI水平较低,对腹腔液的分析显示抑肽酶组中irCT - α1 PI的降低更为明显。两组之间测量的其他变量均无显著差异。所有患者腹腔渗出液和血浆中的白细胞弹性蛋白酶和NP4水平都非常高。与灌洗后其他测量变量均显示腹腔内水平降低相反,灌洗术后腹腔内PSTI水平较高。